Drugs / Pomotrelvir
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05011812 | Aug 2021 → Mar 2022 | COVID-19 | Pardes Biosciences, Inc. | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT05543707 | Sep 2022 → Jan 2023 | COVID-19 | Pardes Biosciences, Inc. | Terminated | Missed primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pomotrelvir | “This is a phase 2 double-blind, randomized study of PBI-0451(Pomotrelvir) in nonhospitalized symptomatic adults with COVID-19.” NCT05543707 ↗ |
| Known as | PBI-0451 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05011812 ↗ |
| Action | Inhibit | “inhibitor of the main protease of coronaviruses” NCT05011812 ↗ |
| Modality | Small molecule | “new chemical entity” NCT05011812 ↗ |
| Route | Oral | “2 × 350 mg tablets administered orally twice daily (BID) (1400 mg/day) with food for 5 days (10 total doses)” NCT05543707 ↗ |